The BENEFIT-HF trial, scheduled to begin enrollment in the months ahead, could significantly increase the number of patients eligible for CVRx's Barostim therapy.
Shockwave Medical, now a part of Johnson & Johnson MedTech, sits at the top of the IVL market, but things are starting to get more competitive. Boston Scientific gained its own IVL system when it acquired Bolt Medical in 2025.
Gene-editing drugs have shown potential to treat a wide variety of diseases, and this will be one of the first in cardiovascular medicine to begin human trials.
Experts involved in its development are confident the agent has the potential to overcome shortcomings associated with conventional oral agents currently on the market.
When combined with a good microphone, "positive findings only" radiology reporting utilizing voice commands may be most efficient style, according to new research.
Post-TAVR stroke is rare, but it can be fatal. A new study in Catheterization and Cardiovascular Interventions examined the issue in great detail, focusing on more than 2,700 patients treated over a two-year stretch.
Gregg Stone, MD, discussing the value of IVUS and OCT over angiography to guide PCI procedures and actually improve outcomes based on a 12,000 patient meta analysis presented at ESC 2023.
NCDR report finds hospitals are seeing improvements but are still struggling to reach pre-COVID treatment thresholds years after pandemic precautions upended longstanding processes.
“Given the dramatic difference in death risk for older adults receiving complex PCI, we suggest that such interventions in this exceptionally vulnerable population should be approached with additional caution," researchers wrote.
The FDA is expected to base its decision in part on the STELLAR clinical trial, which included 163 adult patients treated with subcutaneous sotatercept and 160 patients treated with a placebo.
